1. Leask A, Abraham DJ. TGF‐beta signaling and the fibrotic response. FASEB J. 2004; 18: 816 827.
2. Higley H, Persichitte K, Chu S, Waegell W, Vancheeswaran R, Black С. Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum. 1994; 37: 278 288.
3. Ihn H, Sato S, Fujimoto M, Kikuchi K, Takehara K. Demonstration of interleukin‐2, interleukin‐4 and interleukin‐6 in sera from patients with localized scleroderma. Arch Dermatol Res. 1995; 287: 193 197.
4. Kreuter A, Hyun J, Skrygan M et al. Ultraviolet al‐induced downregulation of human beta‐defensins and interleukin‐6 and interleukin‐8 correlate with clinical improvement in localized scleroderma. Br J Dermatol. 2006; 155: 600 607.
5. Yamamoto T. Chemokines and chemokine receptors in scleroderma. Int Arch Allergy Immunol. 2006; 140: 345 356.
6. Gambichler T, Skrygan M, Labanski AA, Kolios AG, Altmeyer P, Kreuter A. Significantly increased CCL5/RANTES and CCR7 mRNA levels in localized scleroderma. Regul Pept. 2011; 170:4 6.
7. Fett N, Werth VP. Update on morphea. Part I. Epidemiology, clinical presentation, and pathogenesis. Journal of the American Academy of Dermatology. 2011;64(2):217‐28.
8. Saxton‐Daniels S, Jacobe HT. An evaluation of long‐term outcomes in adults with pediatric‐onset morphea. Archives of Dermatology. 2010;146(9):1044‐5.
9. Asano Y, Fujimoto M, Ishikawa O, Sato S, Jinnin M, Takehara K, et al. Diagnostic criteria, severity classification and guidelines of localized scleroderma. Journal of Dermatology. 2018;45(7):755‐80.
10. Ресурсы и деятельность медицинских организаций дерматовенерологического профиля. Заболеваемость инфекциями, передаваемыми половым путем, заразными кожными болезнями и заболеваниями кожи за 2017-2018 годы (статистические материалы). Москва 2019. Стр. 208.
11. Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol. 2006;18(6):606 613.
12. Orozco-Covarrubias L, Guzman-Meza A, Ridaura-Sanz C, Carrasco Daza D, Sosa-de-Martinez C, Ruiz-Maldonado R. Scleroderma ‘en coup de sabre’ and progressive facial hemiatrophy. Is it possible to differentiate them? J Eur Acad Dermatol Venereol. 2002; 16: 361 366.
13. Kister I, Inglese M, Laxer RM, Herbert J. Neurologic manifestations of localized scleroderma: a case report and literature review. Neurology. 2008,4;71(19).
14. Florez-Pollack S, Kunzler E, Jacobe HT. Morphea: Current concepts. Clinics in Dermatology. 2018;36: 475 486.
15. Gorkiewicz-Petkow A., Kalinska-Bienias A. Systemic involvement in localized scleroderma/morphea. Clinics in Dermatology. 2015; 33: 556 562.
16 Zulian. F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira S, Punaro M G, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford). 45 (2006):614-620.
17. Tollefson M M , Witman P M. En coup de sabre morphea and Parry-Romberg syndrome: a retrospective review of 54 patients.J Am Acad Dermatol. 2007; 56:257-263.
18. Weibel L, Laguda B, Atherton D, Harper J I. Misdiagnosis and delay in referral of children with localized scleroderma. Br J Dermatol.2011; 165:1308-1313.
19. Piram M,. McCuaig C C, Saint-Cyr C, Marcoux D, Hatami A, Haddad, et al. Short- and long-term outcome of linear morphea in children. Br J Dermatol. 2013; 169:1265-1271
20. Blaszczyk M , Krolicki L, Krasu M, Glinska O, Jablonska S. Progressive facial hemiatrophy: central nervous system involvement and relationship with scleroderma en coup de sabre. J Rheumatol.2003; 30: 1997-2004.
21. Christen-Zaech S, Hakim M.D, Afsar F.S, Paller A.S. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol. 2008; 59:385-396.
22. Jorre S. Mertens, Marieke M. B. Seyger, Rogier M. Thurlings, Timothy R. D. J. Radstake, Elke M. G. J. de Jong. Morphea and Eosinophilic Fasciitis: An UpdateAm J Clin Dermatol. 2017; 18(4): 491 512.
23. George R, George A, and Kumar TS. Update on Management of Morphea (Localized Scleroderma) in Children. Indian Dermatol Online J. 2020 Mar-Apr; 11(2): 135 145.
24. Arkachaisri T, Fertig N, Pino S, Medsger TA Jr. Serum autoantibodies and their clinical associations in patients with childhood- and adultonset linear scleroderma. A single-center study. J Rheumatol. 2008; 35: 2439 2444.
25. Knobler R, Moinzadeh P, Hunzelmann N, et al. European Dermatology. Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. J Eur Acad Dermatol Venereol. 2017; 31:1401-1424.
26. Sato S, Fujimoto M, Kikuchi K, et al. Soluble CD4 and CD8 in serum from patients with localized scleroderma. Arch Dermatol Res. 1996; 288: 358-362.
27. Clements PJ. Penicillamine in the treatment of systemic sclerosis. Curr Rheumatol Rep. 1999 Oct;1(1):38-42.
28. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008; 58: 3902 12.
29. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35:35 42.
30. Krieg T, Takehara K. Skin disease: a cardinal feature of systemic sclerosis. Rheumatology (Oxford). 2009; 48(3): 14-18.
31. Desbois A C, Cacoub P. Systemic sclerosis: An update in 2016. Autoimmun Rev. 2016 May;15(5):417-26.
32. Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis:an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737-2747.